<code id='E7B7FD62B5'></code><style id='E7B7FD62B5'></style>
    • <acronym id='E7B7FD62B5'></acronym>
      <center id='E7B7FD62B5'><center id='E7B7FD62B5'><tfoot id='E7B7FD62B5'></tfoot></center><abbr id='E7B7FD62B5'><dir id='E7B7FD62B5'><tfoot id='E7B7FD62B5'></tfoot><noframes id='E7B7FD62B5'>

    • <optgroup id='E7B7FD62B5'><strike id='E7B7FD62B5'><sup id='E7B7FD62B5'></sup></strike><code id='E7B7FD62B5'></code></optgroup>
        1. <b id='E7B7FD62B5'><label id='E7B7FD62B5'><select id='E7B7FD62B5'><dt id='E7B7FD62B5'><span id='E7B7FD62B5'></span></dt></select></label></b><u id='E7B7FD62B5'></u>
          <i id='E7B7FD62B5'><strike id='E7B7FD62B5'><tt id='E7B7FD62B5'><pre id='E7B7FD62B5'></pre></tt></strike></i>

          
          WSS
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive